Tag: CNAT

PROW, RNN & Extended Watchlist

Record-Setting ‘Green Rush’ Begins to Subside
–
Like all good things, the frenzied buying of countless pot stocks largely came to an end during yesterday’s session. It was a historic week; an overwhelming trend caused by sheer excitement over Colorado’s precedent-setting entry into the post-prohibition era, and we were happy to cover every step, taking profits along the way! Granted, the main wave of hysteria is now over, but our continued interest in the sector as a whole will not wane. As we stated previously, this story has only just begun to be written. Even as many of the huge runners we’ve tracked began to pull back, others maintained their trends, and still others came down to find support only to rebound and provide bounce opportunities. Rest assured, we will remain hot on the trail of any possible chance at added profits within this sector that has been so good to us for so long a time. For now, it’s time to shift gears and talk about some of our other interests that were forced to the back burner in all the excitement.

Progress Watch Corp. PROW

PROW has brought us some really impressive gains in the short time that we’ve been including it in our reports. When we first began talking about it (12/20/13, trading at .0065) we were especially interested in its tight share structure. That day, we said that the 50DMA rising sharply toward the 200DMA “should lead to a golden cross in the weeks and months ahead.”  That golden cross is now in progress as the stock ran into the close yesterday, attaining four cents, an increase of 515% off of the bottom we observed just twelve trading sessions ago.

As the value of the stock increases, we’re going to be looking for support levels to hold at areas of previous resistance. In the event of any pullbacks, we would like to see support hold at .025, and below that, .013, in order to remain bullish on PROW.

Rexhan Pharmaceuticals, Inc. RNN

Back on December 11th, we tagged RNN for the first time in our extended watchlist, and were rewarded with an intraday run of 26% from .4026 to  .5179. Even as marijuana stocks were breaking out over the past couple of days, we were still tracking this stock’s impressive run via our extended watchlists, and yesterday, saw a high of .765. That marks an increase of 90% from our observed low, a figure which is being pushed even higher this morning; pre-market trades have gone off as high as .929, so things could get very interesting from here. This spike seems to have been catalyzed by a recent press announcement from RNN.


The following PR was released under the headline: “RX-3117 has Shown Efficacy Against Gemcitabine-Resistant Human Cancer Cell Lines and a Broad-Spectrum of Anti-Cancer Activity “

ROCKVILLE, Md., Jan 08, 2014 (BUSINESS WIRE) — Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors. RX-3117 is a next-generation cancer cell specific drug candidate that possesses a broad spectrum of anticancer activity with reduced side effects. In an exploratory Phase I clinical trial conducted in Europe, RX-3117 demonstrated oral bioavailability, and safety and tolerability in cancer patients with solid tumors. >> FULL PR

Extended Watchlist:
CNAT, BBRY, IMMU, BLDP, NSPH, RTRX

CNAT, GOGO, UNIS, CAMT & Extended Watchlist

Conatus Pharmaceuticals, Inc. CNAT

We caught CNAT on our scanner this morning, and is definitely a stock we’d like to keep an eye on today, following an FDA-related announcement regarding a drug that the company has under development receiving “Orphan Drug” status. FDA plays have provided us with countless opportunities in the past, especially when the news is untraded upon, so we’ll be interested to see how well CNAT fares today as a result.

SAN DIEGO, Dec. 2, 2013 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (CNAT), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Conatus’ drug candidate emricasan for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The FDA’s Orphan Drug Designation program is intended to encourage the development of drugs and biologics that may provide benefit to patients suffering from rare diseases or conditions.

Conatus is developing emricasan, a first-in-class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death (or apoptosis), for the treatment of patients with chronic liver disease and significant unmet medical need.

GOGO, Inc. GOGO

We have been hot on the trail of GOGO since our first mention on Monday Sept. 16th when it was trading as low as 14.79. We witnessed the stock’s 52-wk high a few weeks later on Nov. 14th (31.55), and then it consolidated to find support at 24.24.

Yesterday, GOGO re-established its 52-wk high at 31.65, and appears to want to gap up and continue its run today. This morning, the company has news out concerning the green light is has received to install its wifi satellite technology on Boeing 747 aircraft. and we’ve seen pre-market trades going off as high as 32.75. From our original alert price, that marks registers as a 121% gain. Heading into today’s session, we’d like to see the previous 52-wk high of 31.55 hold as support on any future pullbacks.

ITASCA, Ill., Dec. 2, 2013 /PRNewswire via COMTEX/ — Gogo (NASDAQ: GOGO), the world leader of in-flight connectivity and a pioneer in wireless in-flight digital entertainment solutions, passed a key milestone in launching its international connectivity service by receiving an STC to install its Ku-satellite technology on Boeing 747-400 aircraft.

Gogo will begin testing the new service immediately and plans to offer the service for customer usage by the first quarter of 2014. The technology will give travelers and crew access to the Internet. The service will also offer passengers Gogo Vision, Gogo’s wireless in-flight entertainment service.

Unilife Corp. UNIS

UNI hits our radar screens as another play with fresh news and a chart that is gapping up premarket. UNIS has a potentially lucrative arrangement in the works with European Pharma giant, Novartis.

YORK, Pa., Dec. 2, 2013 /PRNewswire/ — Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS, ASX: UNS) today announced an agreement with Novartis to supply clinical products from one of its platforms of injectable drug delivery systems for use with one of Novartis’ targeted early-stage pipeline drugs.

Under this agreement, Unilife will supply Novartis with a customized delivery device, consisting of syringe, needle, tubing, controller and pump, to enable administration of a novel investigational Novartis drug into a targeted organ in clinical trials. Unilife has granted Novartis an option for exclusivity under this agreement.


Camtek, Ltd. CAMT

Yesterday wasn’t the first time we’ve mentioned CAMT on our extended watchlist only to see the stock turn in an impressive performance; last Monday, we tagged CAMT as a possible runner, and subsequently witnessed a pop from 4.11-5.29 (+29%). In a repeat of that scenario, yesterday we saw the stock trade from a low of 4.20 on up to 5.75, for a possible gain of 37%

Cheers to anyone who was able to take advantage of those very timely alerts!

Extended Watchlist:
IACH, OMED, ETRM, FRO, DGLY, NAVB